← TNGX: big moves and long-term fundamentals中文

Tango Therapeutics: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 12, 2026 · Reflects: 10-K FY2025 and the 10-Q for Q3 2026

This page is information, not investment advice.

Sources used most:

1. In one paragraph

Last updated Nov 12, 2026. Reflects the 10-K FY2025 and the 10-Q for Q3 2026.

Tango Therapeutics is a clinical-stage cancer drug developer with no approved products and no product sales. Its lead drug, vopimetostat, is a once-daily pill that blocks PRMT5, an enzyme that tumours missing a gene called MTAP depend on. Tango is testing it alone and with Revolution Medicines’ RAS inhibitors (drugs that block growth-signalling RAS proteins), mainly in pancreatic and lung cancer; a second PRMT5 drug, TNG456, targets brain tumours. Tango reports one segment. Revenue has come from a research collaboration with Gilead Sciences: in 2025 it was $62.4M, all from Gilead, including $53.8M of earlier upfront and research option-extension payments recognised at once when the research term ended in August 2025 (10-K FY2025, notes 3 and 15). Revenue was $0 in the first nine months of 2026. Tango remains eligible for up to $300M per licensed program in Gilead milestones, plus royalties (10-K FY2025, note 3). Gilead had licensed four programs by early 2025 (10-K FY2024). Tango funds itself mainly by selling shares.

2. Story so far

Last updated Nov 12, 2026. Reflects filings through Nov 9, 2026.

In short: Tango listed in 2021 through a merger with a SPAC (a listed shell company) and lived for years on Gilead payments and share sales. In 2026 early data pairing vopimetostat with Revolution Medicines’ daraxonrasib in pancreatic cancer changed its plan: it raised $690M at $30 a share in June and now plans a Phase 3 trial (a late-stage study meant to support approval) of the combination as a first treatment, starting in the first half of 2027, which replaces an earlier plan to start a pivotal trial of vopimetostat alone in 2026. In October its board approved a refocus on PRMT5 drugs, including plans to stop some early research and reduce its workforce by about 14%.

Date Milestone Source
Oct 2018; Aug 2020 Gilead collaboration: $50M upfront, then expanded with $125M upfront 10-K FY2025, note 3
Aug 10–11, 2021 Completes its merger with BCTG Acquisition Corp. on Aug 10; TNGX begins Nasdaq trading on Aug 11; $342.1M gross from the merger and simultaneous financing 8-K, 10-K FY2024
May 23, 2024 Stops developing TNG348 after liver toxicity in patients 8-K
Nov 2024 ★ Signs a clinical supply agreement with Revolution Medicines, which supplies daraxonrasib and zoldonrasib at no cost; Tango sponsors and pays for the combination trials 10-K FY2025, note 8
Aug 2025 Gilead research term cut from seven to five years; milestones and royalties stay in effect 10-K FY2025, note 3
Oct 23, 2025 Vopimetostat alone: median progression-free survival (the time by which half the patients’ cancer had worsened or they had died) 7.2 months in second-line pancreatic cancer (after one earlier treatment); raises $225.0M at $8.66 a share Q3 2025 release, 8-K
Jan 8, 2026 CEO Barbara Weber retires; director Malte Peters becomes CEO 8-K
Jun 8, 2026 ★ First combination data: tumours shrank in 11 of 12 pancreatic cancer patients (92%). Yahoo Finance reported a $30.93 close versus $20.22 on Jun 5, a 53% rise (our calculation)1 8-K, Yahoo Finance
Jun 9–11, 2026 ★ Sells 21.17M shares at $30.00 and 1.83M pre-funded warrants (rights to shares paid for almost entirely upfront) at $29.999, for $690.0M gross; says cash should last into 2030 8-K, 10-Q Q2 2026
Aug 26, 2026 The US Food and Drug Administration (FDA) approves Revolution Medicines’ daraxonrasib (Rasonque) for previously treated pancreatic cancer FDA approval letter; AACR
Oct 22–23, 2026 Board approves a refocus on PRMT5 drugs and deprioritises novel target discovery; plans to cut about 14% of the workforce, mostly in research; two other data readouts move to January 2027 8-K
Oct 23, 2026 ★ Updated data: 82% response rate (18 of 22); Phase 3 as a first treatment planned for 1H 2027. Yahoo Finance reported a $23.34 close, down 16% from $27.93 8-K, Yahoo Finance
Nov 9, 2026 Q3: net loss $68.4M; cash $977.5M; the 10-Q warns that daraxonrasib supply for the planned Phase 3 is not yet secured Q3 2026 release, 10-Q Q3 2026
Oct 23, 2026 Start of our coverage: Tango Therapeutics falls 16% despite strong pancreatic cancer data WhyMyStockMoved

3. Latest quarter: did the story change?

Last updated Nov 12, 2026. Reflects Q3 2026 (10-Q and release, Nov 9, 2026).

Bottom line: Q3 brought no new data, since the October update came after the quarter. The loss grew, as research and development (R&D) costs rose and former executives’ stock awards were changed. Cash stayed near $1.0B. The new 10-Q adds a risk: Tango has not yet secured supply of Revolution Medicines’ daraxonrasib for its planned Phase 3 trial.

Driver Last quarter → this quarter Management: before → now Signal
Combination data (vopimetostat + daraxonrasib, pancreatic cancer after earlier treatment) Q2: 92% response rate (11 of 12) → after Q2: 82% (18 of 22), estimated nine-month progression-free survival 88%, all early responses later confirmed (Aug 20 cutoff; European Society for Medical Oncology (ESMO) congress, October). The rate fell in a larger early-stage group; this is not a controlled comparison Phase 3 planned (Oct 23) → unchanged; will also discuss a possible approval path in second-line patients (after one earlier treatment) with regulators (Nov 9) Worse
First pivotal trial Not started → not started Front-line Phase 3 of the combination vs chemotherapy, start 1H 2027 (Oct 23) → unchanged, but the 10-Q adds that there is “no assurance” Tango can secure daraxonrasib supply “on our anticipated timeline” (Nov 9) Watch
Cash and runway Jun 30 $1,014.0M → Sep 30 $977.5M Runway “into 2030” (Jun 9) → cash expected to fund “its current operating plan” (Nov 9; no new date) Unchanged
Spending Net loss Q2 $55.3M → Q3 $68.4M; R&D $48.9M (was $30.8M a year earlier); general and administrative costs $29.2M (was $8.9M) Expects “significant and increasing expenses” (Aug 11) → G&A rise “primarily” from personnel costs, including changes to former executives’ stock awards (Nov 9) Worse
Other trials and readouts Erasca trial start 2H 2026 → enrolling (November); lung data and TNG456 data still pending Lung monotherapy and TNG456 readouts: 2H 2026 (Aug 11) → January 2027 (Nov 9); a ~25-patient trial in pancreatic cancer without the MTAP deletion planned for 1H 2027 Worse

Sources: Q2 2026 release, Q3 2026 release, 10-Q Q2 2026, 10-Q Q3 2026, 8-K, Oct 23.

Unresolved questions: how and when Tango secures daraxonrasib supply for the Phase 3; whether regulators allow a faster path in second-line patients; how long responses last (median progression-free survival not yet reached); and how fast spending rises once Phase 3 starts.

4. Buybacks vs real dilution (5 years)

Last updated Nov 12, 2026. Reflects the equity statements in the 10-K FY2022, 10-K FY2025 and 10-Q Q3 2026.

Dilution in one line: shares outstanding rose 93% from Dec 31, 2021 (Tango’s first year-end as a listed company) to Sep 30, 2026, about 14.9% a year compounded. If you owned 1% of Tango at the end of 2021, you would have owned about 0.52% on Sep 30, 2026 without buying more (our calculation)2. None of the new shares were offset by buybacks. Our scale: High (over 3% a year).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Dec 31, 2021 to Sep 30, 2026FY2022 +0.7%, FY2023 +15.9%, FY2024 +5.4%, FY2025 +26.2%, 9M 2026 +24.5%. Total +93.2% since Dec 31, 2021.0%+20%+40%+60%+80%+100%FY2022: +0.7% in the period; +0.7% since Dec 31, 2021+0.7%FY2022FY2023: +15.9% in the period; +16.7% since Dec 31, 2021+15.9%FY2023FY2024: +5.4% in the period; +22.9% since Dec 31, 2021+5.4%FY2024FY2025: +26.2% in the period; +55.1% since Dec 31, 2021+26.2%FY20259M 2026 (part year): +24.5% in the period; +93.2% since Dec 31, 2021+24.5%9M 2026+93.2%since Dec 31, 2021

Change in the period Total since Dec 31, 2021 Part year

Shares outstanding at period end (all classes): 87.6M on Dec 31, 2021, 169.2M on Sep 30, 2026, +93.2% (our calculation). A bar below zero means the count fell (net buybacks).

Common shares outstanding, from the author's bridge (10-K and 10-Q equity statements); unexercised pre-funded warrants are not counted.

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
9M 2026 (Sep 30, 2026)169.2M+24.5%———
FY2025 (Dec 31, 2025)135.9M+26.2%—$26M42%
FY2024 (Dec 31, 2024)107.7M+5.4%—$29M69%
FY2023 (Dec 31, 2023)102.2M+15.9%—$19M52%
FY2022 (Dec 31, 2022)88.2M+0.7%—$14M57%
FY2021 (Dec 31, 2021)87.6M——$8M21%

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

About 84% of the new shares came from selling stock for cash (our calculation)3.

How we calculated this

Tango has one class of common stock and has never bought any back.

Bridge (millions of shares) 2022 2023 2024 2025 9M 2026 Total
Start of period 87.6 88.2 102.2 107.7 135.9 87.6
Stock plans (options, restricted stock units and employee purchase plan) 0.6 0.8 1.5 3.1 7.0 13.0
Share sales for cash (offerings, private placements and at-the-market sales into the stock market) – 13.2 4.0 22.8 26.3 66.3
Pre-funded warrants exercised – – – 2.3 – 2.3
Buybacks 0 0 0 0 0 0
End of period 88.2 102.2 107.7 135.9 169.2 169.2

Pre-funded warrants are rights to shares bought for nearly the full share price; the October 2025 and June 2026 warrants need a further $0.001 a share on exercise. The 5.06M sold in October 2025 and June 2026 were still unexercised at Sep 30, 2026 and are not in the count (10-Q Q3 2026). On Nov 2, 2026, 169.46M shares were outstanding (10-Q cover).

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2022 — — — — — — 10-K FY2022: no at-the-market sales
2023 — — — 15.54M (13.20M shares + 2.34M pre-funded warrants) $5.15 $80.0M 8-K, Aug 10, 2023
2024 — — — 4.00M $10.75 (our calculation) $43.0M 10-K FY2024: at-the-market sales in January 2024
2025 — — — 25.98M (22.76M shares + 3.23M pre-funded warrants) $8.66 $225.0M 8-K, Oct 24, 2025; 10-Q Q2 2026
2026 to date (Jan 1–Sep 30) — — — 28.15M $26.80 (our calculation) $754.4M 10-Q Q3 2026: 5.15M at-the-market shares for $64.4M ($12.51, our calculation) in Q1; 21.17M shares and 1.83M pre-funded warrants at $30.00 for $690.0M in June; none in Q3

Tango has sold shares for cash every year since 2023 (most of it in June 2026) and has bought none back. Average price is derived (our calculation)4 unless the filing states a fixed offering price.

Basis and details
  • Raised is gross proceeds before fees. Tango has not split its stock.
  • Employee option exercises and stock purchases are excluded.
  • Tango sold no shares under its at-the-market programme (new shares sold into the stock market) in Q3 2026 (10-Q Q3 2026).
  • For reference, Yahoo Finance reported a $24.85 close on Nov 12, 2026 (Yahoo Finance).
Diluted shares and stock pay (disclosed; % is our calculation) 2022 2023 2024 2025 9M 2026
Weighted diluted shares (M)5 87.8 94.6 109.2 116.2 157.2
Stock-based pay ($M) 14.2 19.1 28.9 26.4 52.6
% of revenue6 57% 52% 69% 42% n/a (no revenue)

Sources: 10-K FY2022, 10-K FY2025 and 10-Q Q3 2026; percentages are our calculations.

5. Profit vs cash (latest FY and TTM)

Last updated Nov 12, 2026. Reflects the 10-K FY2025 and the 10-Qs for Q3 2025 and Q3 2026. TTM = the four quarters to Sep 30, 2026 (our calculation)7.

Tango loses money and burns cash, and it reports no adjusted profit measure. In 2025 cash burn was larger than the accounting loss, mainly because revenue came from upfront payments received years earlier; over the past 12 months the loss was larger, mainly because of $58.6M of stock pay, including charges from changing former executives’ awards.

$M FY2025 TTM to Sep 30, 2026
Net loss −101.6 −208.0
Adjusted metric Not reported Not reported
Operating cash flow −138.9 −150.1
Capital spending −1.0 −0.3
Free cash flow (our calculation)8 −139.9 −150.4

The gap between the loss and the cash burn comes from one revenue item and non-cash charges. Grouped by what each means for future profit and cash:

Helps future profit or cash:

  • None identified.

Hurts future profit or cash:

  • Stock-based pay of $26.4M in 2025 ($58.6M TTM, including charges from changing former executives’ awards), a non-cash expense added back: Not a cash cost, but it is a cost in the loss and it adds shares (see section 4).

One-off / no lasting effect:

  • Gilead revenue brought in no cash: $62.4M in 2025 (none in the past 12 months) was recognised from upfront and research option-extension payments received before 2025: It cut the 2025 loss but not the cash burn; revenue was $0 in the first nine months of 2026.
  • Interest income reduced the loss; $2.7M of it in 2025 was non-cash accretion (the gradual rise of bond holdings toward face value): It is subtracted in operating cash flow, so it lowered the loss but brought no cash.
The raw reconciling items
  • Gilead revenue brought in no cash: $62.4M in 2025 (none in the past 12 months) was recognised from upfront and research option-extension payments received before 2025, so it cut the 2025 loss but not the cash burn.
  • Stock-based pay of $26.4M in 2025 ($58.6M TTM) is a non-cash expense added back.
  • Interest income reduced the loss; $2.7M of it in 2025 was non-cash accretion (the gradual rise of bond holdings toward face value) and is subtracted in operating cash flow.

Funding: how long without new money? (our calculation; as of Sep 30, 2026, the latest filed balance sheet)

  • Cash, cash equivalents and marketable securities of about $977.5M would cover about 6.5 years (about 26 quarters) of the trailing-12-month free cash outflow of $150.4M (our calculation)9; in June Tango said its cash should fund operations “into 2030” (8-K, Jun 10), and in November that it expects the cash to fund its current operating plan (Q3 2026 release).
Funding details
  • Tango’s own estimate is shorter than our past-rate path because it plans a Phase 3 trial and preparation for a possible launch.
  • Debt and convertible notes due within 24 months: none; Tango has no debt. Undrawn credit lines: none disclosed.
  • At-the-market programme: up to $400M with Leerink Partners under the Aug 11, 2026 supplement (8-K); no sales in Q3 2026 (10-Q Q3 2026).
  • This is based on past cash flow; spending plans can change it.

Extends the runway:

  • None committed. No credit line, and no money received after Sep 30 is disclosed.

Shortens the runway:

  • None disclosed (no debt, maturities or covenants). The cost of the planned Phase 3 trial is not quantified.

Conditional:

  • The at-the-market programme of up to $400M, which brings in cash only if Tango sells shares.

Cash path (our calculation; an illustration, not a forecast):

At the past rate and with known items, cash would not fall below zero within 5 years; the company itself says its cash will last “into 2030” (8-K, Jun 10), because it expects spending to rise, which this flat-spending illustration does not include.

Illustration, not a forecast.

Cash path: ending cash by quarter (illustration)Start $978M, Q4 2026 $940M, Q1 2027 $902M, Q2 2027 $865M, Q3 2027 $827M, Q4 2027 $790M, Q1 2028 $752M, Q2 2028 $714M, Q3 2028 $677M, Q4 2028 $639M, Q1 2029 $602M, Q2 2029 $564M, Q3 2029 $526M, Q4 2029 $489M, Q1 2030 $451M, Q2 2030 $414M, Q3 2030 $376M, Q4 2030 $338M, Q1 2031 $301M, Q2 2031 $263M, Q3 2031 $226M.$0M$250M$500M$750M$1.00BStart: $978MQ4 2026: $940MQ1 2027: $902MQ2 2027: $865MQ3 2027: $827MQ4 2027: $790MQ1 2028: $752MQ2 2028: $714MQ3 2028: $677MQ4 2028: $639MQ1 2029: $602MQ2 2029: $564MQ3 2029: $526MQ4 2029: $489MQ1 2030: $451MQ2 2030: $414MQ3 2030: $376MQ4 2030: $338MQ1 2031: $301MQ2 2031: $263MQ3 2031: $226MStartQ2 2027Q1 2028Q4 2028Q3 2029Q2 2030Q3 2031

Ending cash (cash, equivalents and marketable securities) Known item

Quarter Starting cash Usual spending Known items Ending cash Sources / notes
Q4 2026 +977.50 −37.59 0.00 +939.91 No completed raise after Sep 30 disclosed
Q1 2027 +939.91 −37.59 0.00 +902.32 Planned Phase 3 start (1H 2027); cost not disclosed
Q2 2027 +902.32 −37.59 0.00 +864.73
Q3 2027 +864.73 −37.59 0.00 +827.14
Q4 2027 +827.14 −37.59 0.00 +789.55
Q1 2028 +789.55 −37.59 0.00 +751.96
Q2 2028 +751.96 −37.59 0.00 +714.37
Q3 2028 +714.37 −37.59 0.00 +676.78
Q4 2028 +676.78 −37.59 0.00 +639.18
Q1 2029 +639.18 −37.59 0.00 +601.59
Q2 2029 +601.59 −37.59 0.00 +564.00
Q3 2029 +564.00 −37.59 0.00 +526.41
Q4 2029 +526.41 −37.59 0.00 +488.82
Q1 2030 +488.82 −37.59 0.00 +451.23
Q2 2030 +451.23 −37.59 0.00 +413.64
Q3 2030 +413.64 −37.59 0.00 +376.05
Q4 2030 +376.05 −37.59 0.00 +338.46
Q1 2031 +338.46 −37.59 0.00 +300.87
Q2 2031 +300.87 −37.59 0.00 +263.27
Q3 2031 +263.27 −37.59 0.00 +225.68 20 quarters shown

Amounts in $M.

At the past rate and with known items, cash would not fall below zero within 5 years; the company itself says its cash will last “into 2030” (8-K, Jun 10), because it expects spending to rise, which this flat-spending illustration does not include. Companies usually raise money well before that; quarters with less than a year of usual spending left are shaded.

What the cash path counts:

  • Usual spending: about −$37.59M a quarter, held flat.
  • Known items: none. Tango has no debt, acquisition payments or quantified capital commitments; the cost of the planned Phase 3 trial is not quantified.
How we calculated this

Usual spending is trailing-12-month free cash flow (−$150.4M, Q4 2025–Q3 2026) ÷ 4 ≈ −$37.59M a quarter, held flat; balances use the unrounded $977.503M and −$37.591M, so displayed figures are rounded. Starting cash is cash, cash equivalents and marketable securities at Sep 30, 2026 ($977.50M). Tango has no debt, acquisition payments or quantified capital commitments, so there are no known items. Not included:

  • Office and lab lease payments ($44.4M in total from 2026, at Dec 31, 2025; 10-K note 7): they are already in operating cash flow.
  • Capital spending: it is already in free cash flow ($0.3M in the past 12 months, $1.0M in 2025). Tango has not disclosed a quantified capital spending plan, so we can’t say whether the past year was unusual against one.
  • Possible Gilead milestones (inflows) and milestones owed under licences: none is dated.
  • The cost of the planned Phase 3 trial, which Tango has not quantified.
  • Severance costs and savings from the October 2026 workforce cut of about 14%, which Tango has not quantified (8-K, Oct 23).

6. Customer and contract exposure

Last updated Nov 12, 2026. Reflects the 10-K FY2025 and the 10-Q Q3 2026.

Almost all of Tango’s revenue to date has come from Gilead (Sesame Therapeutics paid a $0.1M licence fee in 2024), and its lead programme depends on another company’s drug.

Revenue by customer 2023 2024 2025 9M 2026
Gilead (named; our calculation)10 100% ~100% ($42.0M of $42.1M) 100% No revenue

Tango depends on two partners. Gilead supplied its past revenue and may pay future milestones and royalties if the contract’s conditions are met. Revolution Medicines supplies its drugs free of charge under the existing non-exclusive agreement, but supply for the planned Phase 3 is not yet secured.

Contract details
  • Under the Gilead agreement, the research term ended in August 2025. Gilead keeps its licensed programs. Tango can receive up to $300M per program in milestones and royalties, and may co-develop and co-promote up to five licensed programs in the US (10-K FY2025, note 3).
  • Under the November 2024 agreement with Revolution Medicines, it supplies daraxonrasib and zoldonrasib at no cost, Tango sponsors and pays for the trials, and each keeps the rights to its own drug. The agreement is non-exclusive. Tango calls it a related-party deal because of shared management and board relationships (10-K FY2025, note 8).
  • The planned Phase 3 trial pairs vopimetostat with daraxonrasib. Tango says it is “pursuing multiple pathways” to obtain daraxonrasib supply for it (8-K, Oct 23); its Q3 10-Q added a risk factor that there is “no assurance” it can secure that supply “on our anticipated timeline, on commercially reasonable terms, or at all” (10-Q Q3 2026).
  • Erasca supplies its drug ERAS-0015 at no cost under a March 2026 agreement; the combination trial began enrolling in November 2026 (10-Q, Q3 2026 release).
  • Tango’s 10-year Boston lease began in August 2022 (10-K note 7).

7. What to watch

Last updated Nov 12, 2026. Reflects the 10-Q for Q3 2026 and the Q3 2026 release (Nov 9).

Date Item Source
Jan 2027 Lung cancer data for vopimetostat alone; first TNG456 data in lung cancer, glioblastoma and other cancers; Tango’s lung cancer strategy Q3 2026 release
Not dated Securing daraxonrasib supply for the Phase 3, which the 10-Q says is not assured; talks with regulators about a possible approval path in second-line pancreatic cancer 10-Q Q3 2026, Q3 2026 release
1H 2027 Planned start of the randomised Phase 3 trial of vopimetostat + daraxonrasib vs chemotherapy as a first treatment (main goals: response rate and progression-free survival), and of a ~25-patient trial in pancreatic cancer without the MTAP deletion Q3 2026 release
Feb–Mar 2027 (our estimate; not announced) FY2026 results and 10-K; watch for any updated cash-runway guidance 10-K FY2025 (filed Mar 5, 2026)

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 27, 2026$23.34 (Oct 23)$3.9B$2.9B73.0×54.2×n/mn/m+122%−268%$1.0B12 months to Jun 30, 2026
Nov 12, 2026$24.85 (Nov 12)$4.2B$3.2Bn/mn/mn/mn/mn/mn/m$978M12 months to Sep 30, 2026; pre-revenue

Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 9, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Nov 12, 2026 price: official close, CNBC, Yahoo Finance.

Notes and calculations

  1. (30.93 ÷ 20.22 − 1) × 100. ↩

  2. Remaining ownership = 1% × 87.598 ÷ 169.206 ≈ 0.52%; growth = (169.206 ÷ 87.598 − 1) × 100 ≈ 93%; annual growth = [(169.206 ÷ 87.598)^(1 ÷ 4.75) − 1] × 100 ≈ 14.9%. End: 169,206,312 shares at Sep 30, 2026 (10-Q Q3 2026). ↩

  3. (66.3 + 2.3) ÷ (169.2 − 87.6). ↩

  4. Gross proceeds ÷ shares and pre-funded warrants sold. ↩

  5. Loss years: diluted equals basic. The counts include pre-funded warrants from issuance. ↩

  6. Stock pay ÷ revenue. ↩

  7. FY2025 − 9M 2025 + 9M 2026 (10-K FY2025, 10-Q Q3 2026): net loss −$101.594M + $62.845M − $169.249M; operating cash flow −$138.886M + $109.168M − $120.369M; capital spending $1.048M − $0.826M + $0.055M. ↩

  8. Operating cash flow + capital spending, using the signed amounts shown. ↩

  9. ($86.8M + $890.7M) = $977.5M; $977.5M ÷ $150.4M ≈ 6.5 years. ↩

  10. Gilead revenue ÷ total revenue. ↩

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About Tango Therapeutics: Website (external site)Investor relations (external site)SEC filings (external site)